Expert review of anticancer therapy
-
Expert Rev Anticancer Ther · Aug 2019
ReviewCapmatinib for the treatment of non-small cell lung cancer.
Introduction: Activation of the MET pathway through MET amplifications or mutations is present in 3-4% of stage IV non-squamous non-small cell lung cancers (NSCLC). High MET amplifications and exon 14 skipping mutations are associated with poor prognosis: new treatments are needed for these patients. Capmatinib is a highly selective, potent small-molecule MET inhibitor with antitumor activity in NSCLC in vitro and in vivo. ⋯ Expert opinion: In the GEOMETRY Mono-1 study, treatment with capmatinib resulted in high response rates in stage IV NSCLC with MET exon 14 skipping mutations, particularly in first line, supporting testing for this biomarker at the time of diagnosis. Durable responses have been reported and results in MET-amplified NSCLC are eagerly anticipated. In EGFR-mutant NSCLC, notable responses have been observed in combination with an EGFR-tyrosine kinase inhibitor (TKI) in case of acquired resistance to EGFR-TKIs based on high MET amplification.
-
Expert Rev Anticancer Ther · Jul 2019
ReviewAn update on advanced dual-energy CT for head and neck cancer imaging.
Introduction: Dual-energy-computed tomography (DECT) is an advanced form of computed tomography (CT) that enables spectral tissue characterization beyond what is possible with conventional CT scans. DECT can improve non-invasive diagnostic evaluation of the neck, especially for the evaluation of head and neck cancer. Areas covered: This article is a review of current applications of DECT for the evaluation of head and neck cancer, focusing largely on squamous cell carcinoma (HNSCC). ⋯ This will be followed by a review of different DECT applications in diagnostic imaging and radiation oncology, practical and workflow considerations, and various emerging advanced applications for tumor analysis, including the use of DECT datasets for radiomics and machine learning applications. Expert opinion: Using a multi-parametric approach, different DECT reconstructions can be used to improve diagnostic evaluation and surveillance of head and neck cancer, including improving visibility of HNSCC, determination of tumor boundaries and extent, and invasion of critical organs such as the thyroid cartilage. In the future, the large amount of quantitative information on DECT scans may be leveraged for improving radiomic and machine learning models for tumor characterization.
-
Expert Rev Anticancer Ther · May 2019
ReviewOncologic therapies associated with cardiac toxicities: how to minimize the risks.
Recent breakthroughs in cancer treatment has improved the prospects and life expectancy of cancer patients. Therefore, risk of cardiotoxicity induced by oncologic therapies has become an important determinant of patient's survival and quality of life, independently of the oncologic prognosis. Areas covered: This paper provides an overview of the proposed strategies to mitigate the risk of cardiotoxicity. ⋯ Expert opinion: The most effective approach to minimize cardiotoxicity is early identification and early onset of a prophylactic treatment. However, the current standard of cardiac monitor identifies cardiotoxicity only when a functional impairment has already occurred, precluding any chance of effective prevention. The use of troponins to identify subclinical cardiotoxicity, and early treatment with ACE-inhibitors to prevent cardiac dysfunction and cardiac events have recently emerged, and appear to be an effective tool against this complication.
-
Expert Rev Anticancer Ther · Apr 2019
ReviewAnti-BCMA antibodies in the future management of multiple myeloma.
B-cell maturation antigen (BCMA) belongs to the tumor necrosis factor receptor family and is expressed on late B-cells and plasma cells. Serum BCMA is elevated in patients with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), and might represent a novel prognostic and monitoring tool. Serum BCMA levels can predict both progression free survival (PFS) and overall survival (OS). ⋯ Expert opinion: The preliminary preclinical and clinical results from the phase 1 and 2 studies have demonstrated significant activity of the anti-BCMA therapeutic strategies. The main toxicities induced include Cytokine Release Syndrome (CRS) and ocular toxicity. The management of these adverse events remains currently an issue of controversy.
-
Expert Rev Anticancer Ther · Mar 2019
ReviewManagement of immune-related adverse events resulting from immune checkpoint blockade.
Immune checkpoint inhibitors (ICI) are now a standard of care in the treatment of many cancers leading to durable responses in patients with metastatic disease. These agents are generally well tolerated but may lead to the occurrence of immune-related adverse events (irAEs). As any organ may be affected, clinicians should be aware of the broad range of clinical manifestations and symptoms and keep in mind that toxicities may occur late, at any point along a patient's treatment course. ⋯ Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs. Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices.